Navigation Links
Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase (BTK) Patent
Date:12/19/2011

SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today issue notification from the United States Patent & Trademark Office (USPTO, www.uspto.gov) of a patent entitled "Inhibitors of Bruton's Tyrosine Kinase" and specifically claiming "an inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase (BTK)". This U.S. patent 8,088,781 is set to issue on January 3, 2012. 

"We are very pleased to announce to our stakeholders that the USPTO has granted us this patent, which further strengthens our BTK intellectual property portfolio and confirms Pharmacyclics as being the first in the BTK irreversible inhibitor space," said Bob Duggan, Chairman and CEO of Pharmacyclics. "I consider it an honor and recognition of the knowledge, skill, and innovation of the Pharmacyclics employees and other individuals who were involved in the creation of this intellectual property."

About BTK inhibitor, PCI-32765

PCI-32765 is a first-in-class oral, selective, irreversible BTK inhibitor, which Pharmacyclics is developing for the treatment of patients with B-cell malignancies. B-cell maturation is mediated by B-cell receptor (BCR) signal transduction and BTK is an essential part of the signaling pathway. Recent studies indicate that some B-cell lymphomas depend on chronic active signals from the BCR, and that suppression of this signaling by PCI-32765 can induce apoptosis and inhibit cell migration. Pharmacyclics is currently evaluating PCI-32765, in several Phase 2 clinical trials such as mantle cell lymphoma, chronic lymphocytic leukemia, diffuse lar
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... 2014  ResMed (NYSE: RMD ), a pioneer ... to design complete sleep apnea solutions specifically for women, is ... of a good night,s sleep. The Better ... feeling tired is just part of living a busy life. ... critical pillar of health, essential to not only living an ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems (NYSE: ... report results for the fourth quarter of fiscal year ... October 22, 2014.  The news release will be followed ... 2:00 p.m. PT.  The news release and a link ... the company website at: www.varian.com/investor .  To access ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) ... -- may face an increased risk of dying in the next ... 3,000 older Americans, researchers found those who were unable to detect ... times as likely to die in the next five years, versus ... -- the inability to distinguish odors -- was a bigger predictor ...
(Date:10/2/2014)... scientists at The University of Nottingham could lead to ... , A drug resulting from the research, published in ... new hope to sufferers of chronic pain conditions such ... are currently available. , The work, led by Dr ... in collaboration with David Bates, Professor of Oncology in ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... the Engineering and Physical Sciences Research Council (EPSRC) ... vital industrial control systems which run, for example, ... the rail network. , The research will ... malware infiltrating the systems behind our critical national ... Industrial Control Systems (RITICS), based at Imperial College ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... who cares for patients with cancer at The Children,s Hospital ... Junior Faculty Award in Pediatric Oncology. The American Society of ... award during its annual meeting, occurring June 1-5 in Chicago. ... B. Nachman, a pediatric oncologist and Professor of Pediatrics at ...
... TUESDAY, May 8 (HealthDay News) -- Eating too quickly may ... Researchers from Lithuania compared 234 people with type 2 ... those who gobble down their food were 2.5 times more ... while eating. Study participants with diabetes also were more ...
... Branch at Galveston researchers have discovered that a drug ... also have another important use: treating one of the ... rat and cell-culture experiments, the scientists found that metformin, ... in type 2 diabetes, also substantially reduced the effects ...
... physicians, fees under Medicare which in turn influence ... will pay doctors -- the Centers for Medicare and ... American Medical Association advisory panel. A study led by ... Public Health, found that the Medicare and Medicaid agency ...
... Reporter , MONDAY, May 7 (HealthDay News) -- Those suffering ... their symptoms, but a cure has yet to be found. ... may help patients suffer a little less, but side effects ... preparations impact symptoms of the common cold, there is currently ...
... -- The Medical Publishing Insights and Practices (MPIP) ... editors to characterize the persistent and perceived credibility ... potential approaches to resolve it. This unique round ... Recommendations for Closing the Credibility Gap in Reporting ...
Cached Medicine News:Health News:Diabetes drug could treat leading cause of blindness 2Health News:AMA committee recommendations on doctor fees set by Medicare are followed 9 times out of 10 2Health News:Zinc Pills May Shorten Colds, Analysis Suggests 2Health News:Journals and pharma collaborate on new recommendations 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: